Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shionogi Signs ¥20 Billion License With Oncotherapy Science And Enters Cancer Vaccine Business

This article was originally published in PharmAsia News

Executive Summary

Osaka-based Shionogi signed a licensing agreement with Kawasaki-based biotech venture company Oncotherapy Science and obtained exclusive worldwide rights to develop and market the company's cancer vaccines. Billed as the biggest deal between a Japanese drug maker and a domestic drug discovery venture company, the deal includes a one-time payment, milestone fees and royalties estimated at roughly ¥20 billion. Listed in Tokyo Stock Exchange's Mothers market, Oncotherapy Science specializes in developing cancer vaccines. Shionogi will obtain pre-clinical trial vaccine candidates whose efficacy and develop them in house. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC070866

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel